Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

British Journal of Clinical Pharmacology

Volumn 49, Issue 5, 2000, Pages 445-452

  Angus, B J ^a   Smith, M D ^b   Suputtamongkol, Y ^c   Mattie, H ^d   Walsh, A L ^e   Wuthiekanun, V ^a   Chaowagul, W ^f   White, N J ^g  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Sappasitthiprasong Hospital   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^g QUEEN ELIZABETH CENTRAL HOSPITAL   (Malawi)

Author keywords

Burkholderia pseudomallei; Ceftazidime; Continuous infusion; Melioidosis therapy; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMOXICILLIN; CEFTAZIDIME; CHLORAMPHENICOL; CLAVULANIC ACID; COTRIMOXAZOLE; DOXYCYCLINE; CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BURKHOLDERIA PSEUDOMALLEI; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MELIOIDOSIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BACTEREMIA; BIOLOGICAL MODEL; DRUG EFFECT; ECONOMICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; STATISTICAL MODEL;

ADULT; AGED; BACTEREMIA; CEFTAZIDIME; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MELIOIDOSIS; MIDDLE AGED; BURKHOLDERIA PSEUDOMALLEI; CEPHALOSPORINS; LINEAR MODELS; MODELS, BIOLOGICAL; STATISTICS, NONPARAMETRIC;

EID: 0034012806     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00179.x     Document Type: Article

References (44)

1. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemothcr 1989; 24: 281-293.
2. Gilbert DN. Once daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 339-405.
3. Vogelman D, Gudmundsson S, Leggett J. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
4. Drusano G. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32: 289-297.
5. Miglioli P, Xerri L, Palatini P. Influence of the mode of administration on the penetration of ceftazidime into tissues and pleural exudate of rats. Pharmacol 1991; 43: 242-246.
6. Mouton J, Hollander JD. Killing of Pseudomonas acniginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-936.
7. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial J Antimicrob Chemotlier 1999; 43: 309-311.
8. Tumidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27: 10-22.
9. Vondracek TG. Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann Pharmacotlicr 1995; 29: 415-424.
10. Chaowagul W, White NJ, Dance DAB, et al. Melioidosis: a major cause of community-acquired septicaemia in North-Eastern Thailand. J Infect Dis 1989; 129: 890-899.
11. White NJ, Dance DAB, Chaowagul W, et at. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; ii: 697-701.
12. Suputtamongkol Y, Rajchanuvong A, Chaowagul W, et al. Ceftazidime vs Amoxicillin/clavulanate in treatment of severe melioidosis. Clin Infect Dis 1994; 19: 846-853.
13. Dance DAB, Wuthiekanun V, Chaowagul W, White NJ. The antimicrobial susceptibility of Pseudomonas pseiidomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Cliemothcr 1989; 24: 295-309.
14. Smith MD, Wuthiekanun V, Walsh AL, White NJ. Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotic combinations using time-kill studies. J Antimicrob Cttcmother 1994; 33: 145-149.
15. Walsh AL, Smith MD, Wuthiekanun V, et al. Prognostic significance of quantitative bacteraemia in septicamic melioidosis. Clin Infect Dis 1995; 21: 1498-1500.
16. Wuthiekanun V, Dance DAB, Wattanagoon Y, et al. The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Mcd Alicrobiol 1990; 33: 121-126.
17. Dance DAB, Wuthiekanun V, Naigowit P, et al. Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 2ONE._/ Clin Pathol 1989; 42: 645-648.
18. Rajchanuvong A, Chaowagul W, Suputtamongkol Y, et al. A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance Treatment Melioidosis. Trans R Soc Trop Mcd Hyg 1995; 89: 546-549.
19. van Dalen R, Vree TB, Baars AM, et al. Dosage adjustment for ceftazidime in patients with impaired renal function. EnrJ Clin Pharmacol 1986; 30: 597-605.
20. Myers C, Blumer J. Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography. Antimicrob Agents Chcmothcr 1983; 24: 343-346.
21. Cockcroft DW, Gault MW. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-42.
22. Robertshaw M, Lai KN, Swaminathan R. Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. BrJ Clin Pharmacol 1989; 28: 275-280.
23. Suputtamongkol Y, Hall AJ, Dance DAB, et al. The Epidemiol Melioidosis Ubon Ratchatani, North East Thailand. Int J Epidcmiol 1994; 23: 1082-1090.
24. Richards D, Brogden R. Ceftazidime: A review of its antibacterial activity, phamacokinetic properties and therapeutic use. Drugs 1985; 29: 105-161.
25. Sommers DK, Walters L, Van Wyk M, et al. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Oiemother 1983; 23: 892-896.
26. Ljungberg B, Ehle-Nilsson I. Advancing age and acute infection influence the kinetics of ceftazidime. ScandJ Infect Dis 1989; 21: 327-332.
27. Leroy A, Leguy F, Borsa F, et al. Pharmacokinetics of ceftazidime in normal and uraemic subjects. Antimicrob Agents Chemotlier 1984; 25: 638-642.
28. Lin M, Wang L, HuangJ. Single and multiple dose pharmacokinetics of ceftazidime in infected patients with varying degrees of renal function.,/ Clin Pliannacol 1989; 29: 331-337.
29. Vinks AA, Brimicombe RW, Heijemian HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and phamiacokinetics. J Antimocrob Chemother 1997; 40: 125-133.
30. Ganzinger U, Kleinberger G, Lenz K, et al. Phamiacokinetics of ceftazidime and netilimicin in patients with sepsis. Int J Pliannacol Tlicr Toxicol 1987; 25: 354-362.
31. Rondanelli R, Dionigi RV, Regazzi MB, el al. Ceftazidime in the treatment of Psendomonas infections in intensive-care patients. IntJ Clin Phannacol Ttier Toxicol 1986; 24: 457-459.
32. van-Dalen R, Vree T. Phamiacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990; 16: S235-S238.
33. de Kinowski JM, la Coussaye JE, Bressolle F, et al. Multiple dose phamiacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Anlimicrob Agents Chemother 1993; 37: 464-473.
34. Prediction by APACHE Score Lancet 1986; ii: 286-287.
35. el Touny M, el Guinaidy MA, Abd el Barry M, et al Phamiacokinetics of ceftazidime in patients with liver cirrhois and ascites. Antimicrob Agents Chemother 1991; 28: 95-100.
36. Pasko MT, Beam TR, Spooner JA, et al. Safety and phannacokinetics of ceftazidime in patients with chronic hepatic dysfunction. J Antimicrob Chemother 1985; 15: 365-374.
37. Rowland M, Tozer T. Clinical phamiacokinetics: Concepts and applications, 1st edn. Philadelphia, London: Lea & Febiger 1989.
38. Van-der-Auwera P, KlasterskyJ. Study of the influence of protein binding on serum bactericidal titres and killing rates in volunteers receiving ceftazidime, ceftotaxime and ceftriaxone. J Hospital Infection 1990; 15: 23-24.
39. Lam YW, Duroux MH, Gambertoglio JG, et al. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. Antimicrob Agents Chemother 1988; 32: 298-302.
40. Young RJ, Lipman J, Gin T, et al. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997; 40: 269-273.
41. Benko AS, Cappelletty DM, KruseJA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 1996; 40: 691-695.
42. Manduru M, Mihm LB, White RL, et al. In vitro phamiacodynamics of ceftazidime against Pseudomonas aeniginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 1997; 41: 2053-2056.
43. Gentry L. Antimicrobial activity, phamiacokinetics, therapeutic indications and adverse reactions of ceftazidime. Pharmacother 1985; 5: 254-267.
44. Couldry R, Sanbom M, Strayer AH. Continuous infusion of ceftazidime with an elastomeric infusion device Am J Health Syst Pharm 1998; 55: 145-149.